Mannkind (MNKD) Return on Capital Employed (2011 - 2026)
Mannkind (MNKD) reported Return on Capital Employed of 2.34% for Q1 2026, down 2498.0% year-over-year from 0.1% in Q1 2025, and down 71.49% on a QoQ basis from 8.21% in Q4 2025.
Mannkind (MNKD) has 16 years of Return on Capital Employed data on file, last reported at 2.34% in Q1 2026.
- Quarterly Return on Capital Employed fell 2498.0% year-over-year to 2.34% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.34% (down 2498.0% YoY) and the FY2025 annual result came in at 9.19%, down 1139.0% from the prior year.
- Return on Capital Employed retreated to 2.34% in Q1 2026 per MNKD's latest filing, from 8.21% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 27.32% in Q1 2025 and bottomed at 32.7% in Q3 2022.
- The 5-year median for Return on Capital Employed is 2.96% (2023), against an average of 0.95%.
- The widest annual swing landed in 2023, when Return on Capital Employed surged 3116 bps; it then sank 2498 bps in 2026.
- Tracing MNKD's Return on Capital Employed over 5 years: stood at 28.21% in 2022, then jumped by 110 bps to 2.96% in 2023, then surged by 607 bps to 20.91% in 2024, then plunged by 61 bps to 8.21% in 2025, then slumped by 71 bps to 2.34% in 2026.
- Per Business Quant, the three latest MNKD Return on Capital Employed figures stand at 2.34% (Q1 2026), 8.21% (Q4 2025), and 21.21% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | 2.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.34% |
| Dec 31, 2025 | 8.21% |
| Sep 30, 2025 | 21.21% |
| Jun 30, 2025 | 22.35% |
| Mar 31, 2025 | 27.32% |
| Dec 31, 2024 | 20.91% |
| Sep 30, 2024 | 14.13% |
| Jun 30, 2024 | 12.11% |
| Mar 31, 2024 | 8.30% |
| Dec 31, 2023 | 2.96% |
| Sep 30, 2023 | -5.43% |
| Jun 30, 2023 | -12.78% |
| Mar 31, 2023 | -22.74% |
| Dec 31, 2022 | -28.21% |
| Sep 30, 2022 | -32.70% |
| Jun 30, 2022 | -30.43% |
| Mar 31, 2022 | -23.77% |
| Dec 31, 2021 | -20.33% |
| Sep 30, 2021 | -23.94% |
| Jun 30, 2021 | -21.87% |
| Mar 31, 2021 | -33.35% |
| Dec 31, 2020 | -168.47% |
| Sep 30, 2020 | 515.28% |
| Jun 30, 2020 | -149.28% |
| Mar 31, 2020 | -204.08% |
| Dec 31, 2019 | -154.77% |
| Sep 30, 2019 | -169.45% |
| Jun 30, 2019 | -373.19% |
| Mar 31, 2019 | -239.27% |
| Dec 31, 2018 | -5,940.21% |
| Sep 30, 2018 | 1,664.07% |
| Jun 30, 2018 | 809.79% |
| Mar 31, 2018 | 1,550.13% |
| Dec 31, 2017 | 633.87% |
| Sep 30, 2017 | 387.37% |
| Jun 30, 2017 | -1,538.46% |
| Mar 31, 2017 | 2,200.65% |
| Dec 31, 2016 | 704.58% |
| Sep 30, 2016 | -1,621.45% |
| Jun 30, 2016 | 194.98% |
| Mar 31, 2016 | 246.06% |
| Dec 31, 2015 | 521.37% |
| Sep 30, 2015 | -212.39% |
| Jun 30, 2015 | -813.53% |
| Mar 31, 2015 | 4,540.89% |
| Dec 31, 2014 | 1,411.65% |
| Sep 30, 2014 | -1,102.90% |
| Jun 30, 2014 | -182.23% |
| Mar 31, 2014 | -88.48% |
| Dec 31, 2013 | -116.56% |
| Sep 30, 2013 | -475.72% |
| Jun 30, 2013 | 277.51% |
| Mar 31, 2013 | 482.83% |
| Dec 31, 2012 | -170.79% |
| Sep 30, 2012 | -82.98% |
| Jun 30, 2012 | -74.21% |
| Mar 31, 2012 | -71.42% |
| Dec 31, 2011 | -75.39% |
| Sep 30, 2011 | -68.01% |